Treatment of delayed inflammatory response to hyaluronic acid soft tissue filler in a Pfizer-Boosted Moderna-Vaccinated individual with hyaluronidase

We present a case of delayed-type hypersensitivity to hyaluronic acid (HA)-based filler on the face following the Pfizer booster in a Moderna-vaccinated individual. It is the first known case of treatment of the delayed-type hypersensitivity reaction with hyaluronidase following Covid vaccination. Hyaluronidase is a viable option to treat this reaction, particularly for patients who may not benefit from systemic treatment options. With an anticipated fourth round of vaccine boosters on the horizon, there may be an increased incidence of cutaneous adverse events, including the reaction discussed.

Keywords: COVID-19; SARS-CoV-2; Inflammation; Dermal fillers; Hypersensitivity, Delayed; Hyaluronic acid